Psoriasis can be diagnosed at any time of axSpA follow up. Incidence of PsO ⬆️from 16.8% to 26.8% after 6 years Patients with PsO had more peripheral arthritis and higher BMI Abs#1311 @RheumNow https://t.co/IrvHiFqr2m https://t.co/lqCVcF81zA

#clinicalpearls Cervical involvement in RA: is it underestimated? Cohort of 240pts: anterior atlantoaxial subluxation (aAAS) found in n=25 10.4 % patients, 1/3 with no neck pain! Joint restriction OR: 5.8 hx arthroplasty OR:3.6 #Abst1211 #ACR21 @RheumNow https://t.co/KRkDP4ETMu https://t.co/soKTMPiMwy

#RA pts on #baricitinib less likely to discontinue treatment & more likely to achieve remission than pts receiving biologic /other tsDMARD. 👉🏼Results from RA-BE-REAL observational study 👉🏼Bari(2 or 4mg) vs biologic/other tsDMARD Abs#1223 #ACR21 @RheumNow https://t.co/WRN1OCX9Bq https://t.co/UCFF6hAY7G

In 🇦🇺 we're delighted to be working with @Sarah_L_Mackie et al on the STERLING-PMR trial: - relapsing PMR - pragmatic RCT - MTX (alt LEF) 🇬🇧 @NIHRresearch @LeedsBRC @profbdasgupta @DrMaxYates1 et al 🇦🇺 @nhmrc @CatherineL_Hill @helenkeen73 @drceowen #ACR21 PMR/GCA SG @RheumNow https://t.co/YtnPpHxNqz

Peripheral and axSpA pts with low Vitamin D levels (<30) had worse disease activity and functional impairment (BASDAI, ASDAS, BASFI) compared to pts with normal Vit D levels. Abs#1316 #ACR21 @RheumNow https://t.co/ulIqOAnWtp https://t.co/aMQaTpduJK

@Sineadm15 @bososhea on undiagnosed depression in axSpA. Common, and associated with worse disease activity and quality of life. Abstr#1305 #ACR21 @RheumNow https://t.co/PBH1F3XEGv

#ACR21 Abs#1224. ⬇️ CD39 expression on B cell predicts occurrence of anti-drug Ab in RA on RTX ⭐️13/23 pts on RTX became ADAb+. No diff in concomitant MTX usage ⭐️Baseline CD73 similar, but lower CD39 predictive of ADAb https://t.co/QzbAmXtTmZ @Rheumnow https://t.co/CLtEev69YD

Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM

In this study, ⭕AS pts w/>=2 #comorbidities were associated w/ poorer outcome measures after 2 yrs of ffup vs. pts w/ no comorbids ⭕Pts w/ >=2 comorbids were likely to dc 1st anti-TNF Address comorbidities, ⬆ chances of better outcomes & QoL @RheumNow #ACR21 abs1309 https://t.co/sTnjaC1a1l

Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts. ≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity. Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu